Miguel Forte, a cell therapy expert, has become the chief executive officer of Zelluna Immunotherapy AS, a Norway-based company developing non-engineered T cell receptor therapies for cancer. Dr Forte joins Zelluna from Bone Therapeutics SA where he was chief medical officer. Before that he was chief operating officer of TxCell SA. He currently also serves as chair of the commercialisation committee for the International Society of Cellular Therapy. Dr Forte holds an MD from the University of Lisbon in Portugal and a PhD in immunology from the University of Birmingham in the UK.
Zelluna Immunotherapy announced the appointment on 2 November 2017.
Copyright 2017 Evernow Publishing Ltd